AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Nwam LLC

Nwam LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 3.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,091 shares of the company’s stock after purchasing an additional 265 shares during the period. Nwam LLC’s holdings in AstraZeneca were worth $548,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Fairfield Bush & CO. purchased a new position in AstraZeneca during the second quarter worth about $25,000. ICA Group Wealth Management LLC purchased a new position in shares of AstraZeneca during the 4th quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its holdings in AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after purchasing an additional 390 shares during the last quarter. Sunbelt Securities Inc. purchased a new stake in AstraZeneca in the first quarter valued at approximately $33,000. Finally, Archer Investment Corp lifted its stake in AstraZeneca by 137.0% during the second quarter. Archer Investment Corp now owns 474 shares of the company’s stock worth $34,000 after purchasing an additional 274 shares in the last quarter. 15.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. StockNews.com assumed coverage on shares of AstraZeneca in a research note on Thursday, October 5th. They issued a “strong-buy” rating for the company. Finally, HSBC started coverage on shares of AstraZeneca in a research report on Monday, December 18th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $103.00.

Get Our Latest Analysis on AZN

AstraZeneca Trading Down 1.5 %

Shares of AstraZeneca stock opened at $66.25 on Thursday. The company has a fifty day simple moving average of $65.72 and a 200-day simple moving average of $66.79. The stock has a market cap of $205.37 billion, a price-to-earnings ratio of 34.87, a PEG ratio of 1.19 and a beta of 0.49. The company has a current ratio of 0.79, a quick ratio of 0.60 and a debt-to-equity ratio of 0.60. AstraZeneca PLC has a 12-month low of $61.73 and a 12-month high of $76.56.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its earnings results on Wednesday, November 8th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.03. The business had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $11.55 billion. AstraZeneca had a net margin of 13.10% and a return on equity of 30.30%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.84 EPS. On average, equities analysts forecast that AstraZeneca PLC will post 3.64 EPS for the current fiscal year.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.